23rd Jul 2015 08:38
LONDON (Alliance News) - Allergy Therapeutics PLC Thursday said it expects to post revenue growth of 11% for its recently ended financial year at constant currency, although its reported figures will be hit the weakening of the euro.
The specialist pharmaceutical company expects to post revenue at constant currency of GBP46.6 million for the year to end-June, compared to GBP42.0 million a year before. At actual exchange rates it expects to post revenue of GBP43.2 million, which it said is "slightly ahead of analyst expectations."
Allergy Therapeutics said it is working to expand its portfolio into other segments of the allergy market, and is developing a house dust mite allrgy treatment Acarovac Quattro.
It plans to strengthen its position in Europe through both organic growth and mergers and acquisitions, it said.
Shares in Allergy Therapeutics are trading up 5.5% at 24.12 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.